Barrx HaloFlex Generator - Brand Name Only

The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 is seeking to procure a Barrx HaloFlex Generator (Model 1190A-115A) through a brand name only solicitation. This radiofrequency therapy system is required by the San Francisco VA Medical Center specifically for treating dysplastic Barrett's esophagus and serves as a replacement generator compatible with existing medical accessories. The procurement is justified as a single source acquisition due to the device's proprietary features including controlled radiofrequency energy delivery, multiple applicator compatibility, real-time feedback systems, and safety features with proven clinical effectiveness. Market research conducted through the FDA device database identified over 100 approved devices but none meeting the specific compatibility requirements. The solicitation operates under FAR Part 13 simplified acquisition procedures with evaluation based solely on price, and quotes must be submitted via email to Contracting Officer Leah Smith by 11:00 AM PDT on July 21, 2025.

This procurement is designated as a total small business set-aside under the Simplified Acquisition Threshold, with the acquisition limited to small business distributors through application of the Non-Manufacturer Rule. Several Service-Disabled Veteran-Owned Small Business distributors have been identified as capable of providing the required equipment, though no specific incumbent contractors are mentioned in the documentation. The solicitation calls for delivery of a single unit (quantity: 1) of the HaloFlex Energy Generator, with the delivery date to be determined upon contract award. The procurement value falls under the $250,000 Simplified Acquisition Threshold and is classified under NAICS code 339112 for Surgical and Medical Instrument Manufacturing. Performance will take place at the San Francisco VA Medical Center in San Francisco, California, where the specialized medical equipment will be integrated into existing treatment protocols for esophageal conditions.